Alphamab Oncology is a biopharmaceutical company dedicated to the development, manufacturing and commercialization of cutting-edge innovative biotherapeutics for cancer treatment. On December 12, 2019, Alphamab Oncology was listed on the Main Board of Hong Kong Stock Exchange (Stock Code: 9966.HK). Leveraging proprietary platforms, including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payloads, dual-payload ADCs, and high-concentration subcutaneous formulations, the Company has built a differentiated and globally competitive pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies.
We are actively looking for partners in the following areas:
Cooperation Based on Technology Platforms:
● Partnership with our proprietary glycan-specific conjugation, linker-payloads, dual-payload ADCs, bispecific antibodies, high-concentration subcutaneous formulations and single-domain antibodies platforms.
Collaboration Based on Core Innovative Products:
● KN035: PD-L1 Single-Domain Antibody, Subcutaneous Formulation
● KN026: Anti-HER2 Bispecific Antibody (Overseas Rights)
● JSKN003: Anti-HER2 Biparatopic ADC (Overseas Rights)
Collaboration Based on Emerging Innovative ADC Products:
● JSKN016: TROP2/HER3 Bispecific ADC
● JSKN033: Anti-HER2 Bispecific ADC Subcutaneous Co-formulation
● JSKN022: PD-L1/αvβ6 Bispecific ADC
● JSKN027: PD-L1/ VEGFR2 Bispecific ADC (IND 2026)
● JSKN021: EGFR/HER3 Dual-Payload Bispecific ADC (IND 2026)
We Are Now Open For
Licensing
Co-development
Strategic
Partnership
NewCo
...
Our Partners
If you have an interest in one of these areas, please direct your inquiry to bd@alphamabonc.com
